Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-003288-36
    Sponsor's Protocol Code Number:COMP001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-07-17
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-003288-36
    A.3Full title of the trial
    The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression (P-TRD)
    Seguridad y eficacia de la psilocibina en participantes con depresión refractaria al tratamiento (P-TRD)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
    Seguridad y eficacia de la psilocibina en participantes con depresión refractaria al tratamiento
    A.3.2Name or abbreviated title of the trial where available
    Psilocybin in Participants with Treatment Resistant Depression (P-TRD)
    Psilocibina en participantes con depresión resistente al tratamiento (P-DRT)
    A.4.1Sponsor's protocol code numberCOMP001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCOMPASS Pathways, Ltd
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCOMPASS Pathways, Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCOMPASS Pathways, Ltd.
    B.5.2Functional name of contact pointEkaterina Malievskaia
    B.5.3 Address:
    B.5.3.1Street Address16 Old Bailey
    B.5.3.2Town/ cityLondon
    B.5.3.3Post codeEC4M 7EG
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number079 2087 6562
    B.5.6E-mailkatya@compasspathways.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePsilocybin 5 mg
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPSILOCYBIN
    D.3.9.1CAS number 520-52-5
    D.3.9.3Other descriptive namePsilocybin
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePsilocybin 1 mg
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPSILOCYBIN
    D.3.9.1CAS number 520-52-5
    D.3.9.3Other descriptive namePsilocybin
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Treatment-Resistant Depression (P-TRD)
    Depresión resistente al tratamiento (DRT)
    E.1.1.1Medical condition in easily understood language
    Treatment-Resistant Depression
    Depresión resistente al tratamiento
    E.1.1.2Therapeutic area Psychiatry and Psychology [F] - Mental Disorders [F03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10025454
    E.1.2Term Major depressive disorder, recurrent episode
    E.1.2System Organ Class 100000004873
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10025463
    E.1.2Term Major depressive disorder, single episode
    E.1.2System Organ Class 100000004873
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The main purpose of this study is to allow COMPASS to determine the optimal dose of psilocybin, either 10 mg or 25 mg. The intent of the primary efficacy analysis is to demonstrate superiority of at least one therapeutic dose of psilocybin (10 mg or 25 mg) versus the 1 mg psilocybin via the following objectives.
    The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg or 10 mg) compared to 1 mg, administered under supportive conditions to adult participants with TRD, in improving depressive symptoms, as assessed by the change in the Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline. Baseline is defined as the assessment score obtained on Day 1. The primary timepoint is Week 3; this variable will be analysed for the change from Baseline to Day 1, and Weeks 1, 3, 6, 9, and 12.
    El objetivo principal de este estudio es permitir que COMPASS determine la dosis óptima de psilocibina, bien 10 mg, o 25 mg. El propósito del análisis principal de la eficacia es demostrar la superioridad de al menos una dosis terapéutica de psilocibina (10 mg o 25 mg) frente a 1 mg de psilocibina a través de los siguientes objetivos.
    El objetivo principal de este estudio es evaluar la eficacia de la psilocibina (25 mg o 10 mg) en comparación con 1 mg, administrada bajo condiciones de apoyo a adultos con TRD, en la mejoría de los síntomas depresivos, de acuerdo con el cambio en la puntuación total con respecto al valor inicial de la escala de puntuación de la depresión de Montgomery-Asberg (MADRS, Montgomery Asberg Depression Rating Scale). El valor inicial se define como la puntuación de la evaluación obtenida el día 1. El momento principal es la semana 3; esta variable se analizará para el cambio con respecto al valor inicial hasta el día 1 y las semanas 1, 3, 6, 9 y 12.
    E.2.2Secondary objectives of the trial
    The secondary objectives are:
    • To assess the efficacy of psilocybin compared to 1 mg psilocybin on:
    oProportion of participants with response defined as a ≥ 50% decrease in MADRS total score from Baseline to Week 3. This will also be assessed at Day 1 and at Weeks 1, 6, 9, and 12.
    oProportion of participants in remission defined as the participants with a MADRS total score ≤ 10 at Week 3. This will also be assessed at Day 1 and at Weeks 1, 6, 9, and 12.
    oProportion of responding participants who sustained a response up to Week 12 defined as those with ≥ 50% decrease in MADRS total score on or before Week 6 and remaining at Week 12.
    Los objetivos secundarios son:
    •Evaluar la eficacia de la psilocibina en comparación con 1 mg de psilocibina en:
    oLa proporción de participantes con respuesta definida como una disminución de ≥ 50 % en la puntuación total con respecto al valor inicial de la MADRS hasta la semana 3. Esto se evaluará también en el día y las semanas 1, 6, 9 y 12.
    oLa proporción de participantes en remisión, definida como los participantes con una puntuación total de la MADRS de ≤ 10 en la semana 3. Esto se evaluará también en el día 1 y las semanas 1, 6, 9 y 12.
    oLa proporción de participantes respondedores que mantuvieron una respuesta hasta la semana 12, definida como aquellos participantes con una disminución de ≥ 50 % en la puntuación total de la MADRS en o antes de la semana 6 y que continuaba en la semana 12.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Signed ICF.
    2. 18 years of age or older at Screening (V1).
    3. At least moderate MDD (single or recurrent episode as defined by DSM 5; if single episode, duration of ≥ 3 months and ≤ 2 years) based on medical records, clinical assessment and documented completion of the version 7.0.2 MINI.
    4. HAM D 17 (17 item) score ≥ 18 at Screening (V1) and at Baseline (V2).
    5. Failure to respond to an adequate dose and duration of 2, 3, or 4 pharmacological treatment for the current episode as determined through the MGH ATRQ. Failure includes inadequate response to an adequate duration and dose or failure to reach an adequate dose and duration due to lack of tolerance. Augmentation with an add on treatment counts as a second treatment.
    6. McLean Screening Instrument for Borderline Personality Disorder < 7 at Screening (V1).
    7. Have successfully discontinued all serotonergic medications at least 2 weeks prior to Baseline (V2).
    8. Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.
    1. FCI firmado.
    2. Ser mayor de 18 años de edad en la selección (V1).
    3. Tener al menos TDM moderada (episodio único o recurrente según se define en el DSM 5; en el caso de episodio único, una duración de ≥ 3 meses y ≤ 2 años) en base a la historia clínica, la evaluación clínica y la cumplimentación verificada de la MINI, versión 7.0.2.
    4. Una puntuación de ≥ 18 en la HAM D 17 (17 ítems) en la selección (V1) y al inicio del estudio (V2).
    5. No responder a una dosis y duración adecuadas de 2, 3 o 4 tratamientos farmacológicos para el episodio actual según se determine a través del MGH ATRQ. El fracaso incluye una respuesta inadecuada a una duración y dosis adecuadas o no poder alcanzar una dosis y duración adecuadas debido a la falta de tolerancia. El aumento con un tratamiento complementario cuenta como un segundo tratamiento.
    6. Instrumento de cribado de McLean para el trastorno límite de la personalidad de < 7 en la selección (V1).
    7. Haber interrumpido con éxito todos los medicamentos serotoninérgicos al menos 2 semanas antes de iniciar el estudio (V2).
    8. Ser capaz de completar todos los instrumentos de evaluación requeridos sin ninguna ayuda ni modificación de las evaluaciones protegidas por derechos de autor, y cumplir con todas las visitas del estudio.
    E.4Principal exclusion criteria
    Psychiatric Exclusion Criteria:
    1. Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, or borderline personality disorder, as assessed by medical history and a structured clinical interview (version 7.0.2 MINI).
    2. Prior electroconvulsive therapy and/or intravenous ketamine for current episode.
    3. Current cognitive behavioural therapy (CBT) that will not remain stable for the duration of the study. CBT cannot be initiated within 21 days of baseline.
    4. Current (< 1 year) alcohol or drug abuse as defined by DSM 5 at Screening (V1).
    5. Significant risk of suicide based on the SSTS prior to randomisation defined as (a) a score of “3” or “4” on Questions 2 or 13; or (b) a score of “2” or higher on Questions 1a, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 14 over the past 13 months. Or, if active suicidal activity or ideation during the current episode, eligibility will be determined at the investigator’s discretion in conjunction with the medical monitor.
    6. Depression secondary to other severe medical conditions.
    7. Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin.
    General Medical Exclusion Criteria:
    8. Women who are pregnant, nursing, or planning a pregnancy. Participants who are sexually active must agree to use a highly effective contraceptive method throughout their participation in the study. Women of child bearing potential must have a negative urine pregnancy test at Screening (V1) and Baseline (V2).
    9.Cardiovascular conditions: recent stroke (< 1 year from signing of ICF), recent myocardial infarction (< 1 year from signing of ICF), uncontrolled hypertension (blood pressure > 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF.
    10.Uncontrolled OR insulin dependent diabetes.
    11.Seizure disorder.
    12.Positive urine drug screen for illicit drugs or drugs of abuse at V1 and V2. Any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator’s discretion in conjunction with the medical monitor.
    13.Current enrolment in any investigational drug or device study or participation in such within 30 days of Screening (V1).
    14.Current enrolment in an interventional study for depression or participation in such within 30 days of Screening (V1).
    15.Abnormal and clinically significant results on the physical examination, vital signs, ECG, or laboratory tests at Screening (V1).
    16.Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study.
    1. Antecedentes pasados o actuales de esquizofrenia, trastorno psicótico (a menos que sea inducido por sustancias o debido a una enfermedad), trastorno bipolar, trastorno delirante, trastorno paranoide de la personalidad, trastorno esquizoafectivo o trastorno límite de la personalidad, de acuerdo con los antecedentes médicos y una entrevista clínica estructurada (MINI, versión 7.0.2).
    2. Terapia electroconvulsiva previa y/o ketamina intravenosa para el episodio recurrente.
    3. Terapia cognitivo-conductual (TCC) actual que no permanecerá estable durante todo el estudio. La TCC no se puede comenzar en los 21 anteriores al inicio del estudio.
    4. Abuso de alcohol o drogas en la actualidad (< 1 año) según se define en el DSM 5 en la selección (V1).
    5. Riesgo de suicidio significativo en base a la SSTS antes de la aleatorización definido como (a) una puntuación de «3» o «4» en las preguntas 2 o 13; o (b) una puntuación de «2» o superior en las preguntas 1a, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 14 durante los últimos 13 meses. O, en caso de actividad o ideas suicidas activas durante el episodio actual, la idoneidad se determinará a criterio del investigador junto con el monitor médico.
    6. Depresión secundaria a otras enfermedades graves.
    7. Otras circunstancias y conducta personales que se consideren incompatibles con el establecimiento de buenas relaciones o la exposición segura a la psilocibina.
    Criterios generales de exclusión médica:
    8. Mujeres que estén embarazadas, en periodo de lactancia o planeando quedarse embarazas. Los participantes sexualmente activos deben aceptar el uso de un método anticonceptivo altamente eficaz durante toda su participación en el estudio. Las mujeres con capacidad para procrear deben tener un resultado negativo en una prueba de embarazo en orina en la selección (V1) y al inicio del estudio (V2).
    9. Enfermedades cardiovasculares: accidente cerebrovascular reciente (< 1 año antes de la firma del FCI), infarto de miocardio reciente (< 1 año antes de la firma del FCI), hipertensión no controlada (presión arterial > 140/90 mmHg) o arritmia clínicamente significativa en el plazo de 1 año antes de la firma del FCI.
    10. Diabetes no controlada O insulinodependiente.
    11. Trastorno convulsivo.
    12. Resultado positivo en la prueba de detección de drogas en orina para drogas ilegales o drogas adictivas en la V1 y V2. Todo resultado positivo en la prueba de detección de drogas en orina se revisará con los participantes para determinar el patrón de uso, y la idoneidad se determinará a criterio del investigador junto con el monitor médico.
    13. Inscripción actual en algún estudio con un medicamento o un dispositivo en fase de investigación o participación en el mismo en los 30 días anteriores a la selección (V1).
    14. Inscripción actual en un estudio intervencionista sobre la depresión o participación en el mismo en los 30 días anteriores a la selección (V1).
    15. Resultados anormales y clínicamente significativos en la exploración física, constantes vitales, ECG o pruebas analíticas en la selección (V1).
    16. Cualquier otra enfermedad cardiovascular, pulmonar, gastrointestinal, hepática, renal u otra afección grave concurrente clínicamente significativas que, en opinión del investigador, puedan interferir en la interpretación de los resultados del estudio o constituir un riesgo para la salud del participante si toma parte en el estudio.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is the change in MADRS total score from Baseline (Day 1) to 3 weeks post psilocybin.
    El criterio de valoración principal es el cambio en la puntuación total con respecto al valor inicial de la MADRS (día 1) hasta 3 semanas después de la administración de psilocibina.
    E.5.1.1Timepoint(s) of evaluation of this end point
    3 Weeks post-psilocybin
    3 semanas después de la administración de psilocibina
    E.5.2Secondary end point(s)
    The secondary endpoints are:
    • The proportion of participants with a response (defined as a ≥ 50% improvement in MADRS total score from Baseline) at Week 3 post psilocybin.
    • The proportion of participants with remission (defined as a MADRS total score ≤ 10) at Week 3 post psilocybin.
    • The proportion of participants who have a sustained response at Week 12.
    • Time to event measures: restart antidepressant medication for any reason, restart medication for continuing depressive symptoms, and relapse from a previously recovered state (clinical judgement, supported by the QIDS SR 16). Participants who withdraw from the study will be censored from the time to event analysis.
    • La proporción de participantes con una respuesta (definida como una mejora de ≥ 50 % en la puntuación total con respecto al valor inicial de la MADRS) en la semana 3 después de la administración de psilocibina.
    • La proporción de participantes en remisión (definida como una puntuación total de la MADRS de ≤ 10) en la semana 3 después de la administración de psilocibina.
    • La proporción de participantes que tienen una respuesta sostenida en la semana 12.
    • Mediciones del tiempo hasta el acontecimiento: reanudación de la medicación antidepresiva por cualquier motivo, reanudación de la medicación por la continuación de los síntomas depresivos y recaída de un estado recuperado previamente (juicio clínico, respaldado por el QIDS SR 16). Los participantes que se retiren del estudio serán censurados del análisis del tiempo hasta el acontecimiento.
    E.5.2.1Timepoint(s) of evaluation of this end point
    The primary endpoint is the change in MADRS total score from Baseline (Day 1) to 3 weeks post psilocybin.
    The secondary endpoints :
    • The proportion of participants with a response (defined as a ≥ 50% improvement in MADRS total score from Baseline) at Week 3 post psilocybin.
    •The proportion of participants with remission (defined as a MADRS total score ≤ 10) at Week 3 post psilocybin.
    •The proportion of participants who have a sustained response at Week 12.
    •Time to event measures: restart antidepressant medication for any reason, restart medication for continuing depressive symptoms, and relapse from a previously recovered state (clinical judgement, supported by the QIDS SR 16). Participants who withdraw from the study will be censored from the time to event analysis.
    Criterio de valoración principal:El criterio de valoración principal es el cambio en la puntuación total con respecto al valor inicial de la MADRS (día -1) hasta 3 semanas después de la administración de psilocibina.
    Los criterios secundarios :
    • La proporción de participantes con una respuesta en la semana 3 después de la administración de psilocibina.
    • La proporción de participantes en remisión en la semana 3 después de la administración de psilocibina.
    • La proporción de participantes que tienen una respuesta sostenida en la semana 12.
    • Mediciones del tiempo hasta el acontecimiento: reanudación de la medicación antidepresiva por cualquier motivo, reanudación de la medicación por la continuación de los síntomas depresivos y recaída de un estado recuperado previamente
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    de dosis fija
    fixed dose
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    3 grupos de tratamiento: tratamiento con 25 mg, tratamiento con 10 mg, tratamiento con 1 mg
    3 treatment arms: 25 mg treatement, 10 mg treatment, 1 mg treatment
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    Czech Republic
    Denmark
    Finland
    Germany
    Ireland
    Netherlands
    Portugal
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days30
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months4
    E.8.9.2In all countries concerned by the trial days30
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 195
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 21
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state31
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 398
    F.4.2.2In the whole clinical trial 398
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants may be offered further treatment in a separate study
    A los participantes se les puede ofrecer un tratamiento posterior en un estudio separado
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-12-28
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-10-25
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:21:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA